Company news

Argent Biopharma Ltd news in 2025

Argent Biopharma Ltd's news releases, calls and decks from 2025, newest first.

View company

A$11m Financing Facility to Complete Strategic Acquisition

November 16, 2025

Quarterly Activities/Appendix 4C Cash Flow Report

October 31, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

August 27, 2025

U.S. In Vivo Study Supports ArtemiC Efficacy

August 24, 2025

RGT Signs Binding Term Sheet to Acquire AusCann Assets

August 18, 2025

EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia

July 7, 2025

Argent BioPharma Enters Germany - Europe's Largest Market

April 23, 2025

Strategic Agreement to Enhance Cannabinoid Development

April 14, 2025

Strategic Collaboration Agreement for Malta Facility

April 8, 2025

CannEpil Receives Approval for Prescription in Germany

April 2, 2025

CimetrA Phase IIb Clinical Trial Results

March 16, 2025

Argent BioPharma Expands Pipeline with Promising Drug CimetrA®

March 16, 2025

Exclusive Agreement for Malta Manufacturing Facility

March 11, 2025

Strategic Manufacturing Partnership with ECCPharm Limited

March 4, 2025

Half Year Accounts

February 28, 2025

Corporate Update - Board Change

February 4, 2025

Placing to Raise US$4,500,000

January 6, 2025

Trading Halt

January 2, 2025

Decks in 2025